{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:14Z","timestamp":1783750394531,"version":"3.55.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100024252","name":"Facult\u00e9 de pharmacie, Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01653-1","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:53:52Z","timestamp":1782860032000},"page":"953-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review"],"prefix":"10.1007","volume":"65","author":[{"given":"\u00c9milie","family":"Pilote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"1653_CR1","unstructured":"World Health Organization (WHO). HIV\/AIDS \u2013 Global Health Observatory (GHO) data [Internet]. 2024. https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids. Cited 24 June 2025."},{"key":"1653_CR2","unstructured":"UNAIDS. Global HIV & AIDS statistics\u2014Fact sheet [Internet]. UNAIDS; 2025. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Updated 10 July 2025; Cited 6 Oct 2025."},{"key":"1653_CR3","volume-title":"DiPiro\u2019s pharmacotherapy: a pathophysiologic approach","author":"PL Anderson","year":"2023","unstructured":"Anderson PL, Brooks KM, Fletcher CV. Human Immunodeficiency Virus Infection. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, editors. DiPiro\u2019s pharmacotherapy: a pathophysiologic approach. 12th ed. New York: McGraw Hill; 2023.","edition":"12"},{"issue":"16","key":"1653_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","volume":"80","author":"KK Scarsi","year":"2020","unstructured":"Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020;80(16):1649\u201376. https:\/\/doi.org\/10.1007\/s40265-020-01379-9.","journal-title":"Drugs"},{"key":"1653_CR5","unstructured":"World Health Organization (WHO). WHO recommends dolutegravir as preferred HIV treatment option in all populations [News release]. World Health Organization (WHO); 2019 [Cited 7 Jan 2025. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations."},{"key":"1653_CR6","unstructured":"ViiV Healthcare ULC. Tivicay Product Monograph. Quebec: ViiV Healthcare ULC; 2021. https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_CA\/tivicay.pdf."},{"issue":"1","key":"1653_CR7","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v23i1.1452","volume":"23","author":"E Mondleki","year":"2022","unstructured":"Mondleki E, Banda CG, Chandiwana NC, Sokhela S, Wiesner L, Venter F, et al. Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV. South Afr J HIV Med. 2022;23(1):a1452. https:\/\/doi.org\/10.4102\/sajhivmed.v23i1.1452.","journal-title":"South Afr J HIV Med"},{"issue":"1","key":"1653_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciy426","volume":"68","author":"ER Elliot","year":"2019","unstructured":"Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68(1):87\u201395. https:\/\/doi.org\/10.1093\/cid\/ciy426.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1653_CR9","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2352-3018(21)00324-6","volume":"9","author":"A Naidoo","year":"2022","unstructured":"Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. Lancet HIV. 2022;9(2):e130\u20138. https:\/\/doi.org\/10.1016\/S2352-3018(21)00324-6.","journal-title":"Lancet HIV"},{"issue":"4","key":"1653_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040915","volume":"12","author":"MM Apetroaei","year":"2024","unstructured":"Apetroaei MM, Velescu BS, Nedea MII, Dinu-Pirvu CE, Draganescu D, Faca AI, et al. The phenomenon of antiretroviral drug resistance in the context of human immunodeficiency virus treatment: dynamic and ever evolving subject matter. Biomedicines. 2024;12(4):915. https:\/\/doi.org\/10.3390\/biomedicines12040915.","journal-title":"Biomedicines"},{"key":"1653_CR11","unstructured":"World Health Organization (WHO). HIV drug resistance \u2013 brief report 2024. Geneva; 2024. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b9c5dba5-4055-46e3-ab42-abdd00f94aa5\/content."},{"issue":"5","key":"1653_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s43440-023-00515-y","volume":"75","author":"A Jakimiuk","year":"2023","unstructured":"Jakimiuk A, Piechal A, Wiercinska-Drapalo A, Nowaczyk A, Mirowska-Guzel D. Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies. Pharmacol Rep. 2023;75(5):1138\u201351. https:\/\/doi.org\/10.1007\/s43440-023-00515-y.","journal-title":"Pharmacol Rep"},{"issue":"10","key":"1653_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S2352-4642(23)00164-5","volume":"7","author":"A Turkova","year":"2023","unstructured":"Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, et al. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet Child Adolesc Health. 2023;7(10):718\u201327. https:\/\/doi.org\/10.1016\/S2352-4642(23)00164-5.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"1653_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-Part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2(4):e38. https:\/\/doi.org\/10.1038\/psp.2013.14.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1653_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/bcp.16335","volume":"91","author":"M Berezowska","year":"2024","unstructured":"Berezowska M, Hayden IS, Brandon AM, Zats A, Patel M, Barnett S, et al. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. Br J Clin Pharmacol. 2024;91(4):1064\u201379. https:\/\/doi.org\/10.1111\/bcp.16335.","journal-title":"Br J Clin Pharmacol"},{"key":"1653_CR16","unstructured":"Elsevier. Embase Database. https:\/\/www.embase.com."},{"key":"1653_CR17","unstructured":"National Library of Medicine (NLM). Medline Database. https:\/\/www.nlm.nih.gov\/medline\/medline_home.html."},{"issue":"3","key":"1653_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bcp.12639","volume":"80","author":"J Zhang","year":"2015","unstructured":"Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80(3):502\u201314. https:\/\/doi.org\/10.1111\/bcp.12639.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1653_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/FTD.0000000000000618","volume":"41","author":"F Parant","year":"2019","unstructured":"Parant F, Miailhes P, Brunel F, Gagnieu MC. Dolutegravir population pharmacokinetics in a real-life cohort of people living with HIV infection: a covariate analysis. Ther Drug Monit. 2019;41(4):444\u201351. https:\/\/doi.org\/10.1097\/FTD.0000000000000618.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1653_CR20","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/jac\/dkz217","volume":"74","author":"C Barcelo","year":"2019","unstructured":"Barcelo C, Aouri M, Courlet P, Guidi M, Braun DL, Gunthard HF, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9):2690\u20137. https:\/\/doi.org\/10.1093\/jac\/dkz217.","journal-title":"J Antimicrob Chemother"},{"key":"1653_CR21","unstructured":"Singh R, Chandasana H, Dooley K.E, Kaplan R, Mwelase N, Grinsztejn B, et al. Population pharmacokinetic analysis of dolutegravir in HIV\/ TB co-infected people with and without rifampicin. (Poster). 17th European AIDS Conference. Basel, Switzerland; 6\u20139 November 2019."},{"issue":"6","key":"1653_CR22","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","volume":"7","author":"KE Dooley","year":"2020","unstructured":"Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial. Lancet HIV. 2020;7(6):e401\u20139. https:\/\/doi.org\/10.1016\/S2352-3018(20)30032-1.","journal-title":"Lancet HIV"},{"issue":"5","key":"1653_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/jac\/dkab022","volume":"76","author":"AN Kawuma","year":"2021","unstructured":"Kawuma AN, Walimbwa SI, Pillai GC, Khoo S, Lamorde M, Wasmann RE, et al. Dolutegravir pharmacokinetics during co-administration with either artemether\/lumefantrine or artesunate\/amodiaquine. J Antimicrob Chemother. 2021;76(5):1269\u201372. https:\/\/doi.org\/10.1093\/jac\/dkab022.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1653_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00215-22","volume":"66","author":"AN Kawuma","year":"2022","unstructured":"Kawuma AN, Wasmann RE, Dooley KE, Boffito M, Maartens G, Denti P. Population pharmacokinetic model and alternative dosing regimens for dolutegravir coadministered with rifampicin. Antimicrob Agents Chemother. 2022;66(6):e0021522. https:\/\/doi.org\/10.1128\/aac.00215-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1653_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/infdis\/jiac174","volume":"226","author":"Z Cindi","year":"2022","unstructured":"Cindi Z, Kawuma AN, Maartens G, Bradford Y, Venter F, Sokhela S, et al. Pharmacogenetics of dolutegravir plasma exposure among Southern Africans with human immunodeficiency virus. J Infect Dis. 2022;226(9):1616\u201325. https:\/\/doi.org\/10.1093\/infdis\/jiac174.","journal-title":"J Infect Dis"},{"issue":"3","key":"1653_CR26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bcp.15604","volume":"89","author":"AN Kawuma","year":"2022","unstructured":"Kawuma AN, Wasmann RE, Dooley KE, Maartens G, Denti P. Drug-drug interaction between rifabutin and dolutegravir: a population pharmacokinetic model. Br J Clin Pharmacol. 2022;89(3):1216\u201321. https:\/\/doi.org\/10.1111\/bcp.15604.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1653_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00430-23","volume":"67","author":"A Kengo","year":"2023","unstructured":"Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, et al. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrob Agents Chemother. 2023;67(11):e0043023. https:\/\/doi.org\/10.1128\/aac.00430-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1653_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01504-23","volume":"68","author":"H Chandasana","year":"2024","unstructured":"Chandasana H, Singh R, Adkison K, Ait-Khaled M, Pene Dumitrescu T. Population pharmacokinetic modeling of dolutegravir\/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1. Antimicrob Agents Chemother. 2024;68(5):e0150423. https:\/\/doi.org\/10.1128\/aac.01504-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1653_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jcph.2494","volume":"64","author":"H Chandasana","year":"2024","unstructured":"Chandasana H, Bush M, Ait-Khaled M, Wynne B, Min S, Mehta R. Population pharmacokinetic analysis of dolutegravir in treatment-experienced adults living with HIV-1. J Clin Pharmacol. 2024;64(11):1407\u201318. https:\/\/doi.org\/10.1002\/jcph.2494.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1653_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/psp4.13244","volume":"14","author":"B Punyawudho","year":"2025","unstructured":"Punyawudho B, Chanruang A, Ueaphongsukkit T, Gatechompol S, Ubolyam S, Cho YS, et al. The population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV: assessment of alternative dosing regimens. CPT Pharmacometrics Syst Pharmacol. 2025;14(1):95\u2013104. https:\/\/doi.org\/10.1002\/psp4.13244.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1653_CR31","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S2352-3018(25)00002-5","volume":"12","author":"ED Weld","year":"2025","unstructured":"Weld ED, Beattie T, Moodley J, Mapendere M, Salles I, Solans BP, et al. Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1\/2 trial. Lancet HIV. 2025;12(6):e428\u201339. https:\/\/doi.org\/10.1016\/S2352-3018(25)00002-5.","journal-title":"Lancet HIV."},{"key":"1653_CR32","doi-asserted-by":"publisher","unstructured":"De Greef J, Comets E, Elens L, Yombi JC, Vincent A, Vandercam B, et al. Pharmacogenetics of dolutegravir and bictegravir plasma and intracellular pharmacokinetics. (Abstract eP165). In: Abstract of the 20th European AIDS conference 2025, October 15\u201318, 2025, Paris, France: HIV Med; 2025. pp. 401\u20133. https:\/\/doi.org\/10.1111\/hiv.70104.","DOI":"10.1111\/hiv.70104"},{"issue":"4","key":"1653_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/jac\/dkad043","volume":"78","author":"S Abdalla","year":"2023","unstructured":"Abdalla S, Compagnucci A, Zheng Y, Treluyer JM, Saidi Y, Ramos JT, et al. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial. J Antimicrob Chemother. 2023;78(4):1041\u20139. https:\/\/doi.org\/10.1093\/jac\/dkad043.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1653_CR34","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40262-023-01289-5","volume":"62","author":"H Chandasana","year":"2023","unstructured":"Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, et al. Population pharmacokinetic modeling of dolutegravir to optimize pediatric dosing in HIV-1-infected infants, children, and adolescents. Clin Pharmacokinet. 2023;62(10):1445\u201359. https:\/\/doi.org\/10.1007\/s40262-023-01289-5.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1653_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/jpids\/piae076","volume":"13","author":"H Waalewijn","year":"2024","unstructured":"Waalewijn H, Wasmann RE, Bamford A, Gibb DM, McIlleron HM, Colbers A, et al. Population pharmacokinetics of dolutegravir in African children: results from the CHAPAS-4 trial. J Pediatric Infect Dis Soc. 2024;13(9):496\u2013500. https:\/\/doi.org\/10.1093\/jpids\/piae076.","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"4","key":"1653_CR36","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1016\/S2352-3018(24)00312-6","volume":"12","author":"A Naidoo","year":"2025","unstructured":"Naidoo A, Waalewijn H, Naidoo K, Letsoalo M, Cromhout G, Sewnarain L, et al. Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study. Lancet HIV. 2025;12(4):e273\u201382. https:\/\/doi.org\/10.1016\/S2352-3018(24)00312-6.","journal-title":"Lancet HIV."},{"issue":"5","key":"1653_CR37","doi-asserted-by":"publisher","first-page":"e1200","DOI":"10.1093\/cid\/ciaa1861","volume":"73","author":"L Dickinson","year":"2021","unstructured":"Dickinson L, Walimbwa S, Singh Y, Kaboggoza J, Kintu K, Sihlangu M, et al. Infant exposure to dolutegravir through placental and breast milk transfer: a population pharmacokinetic analysis of DolPHIN-1. Clin Infect Dis. 2021;73(5):e1200\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa1861.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1653_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/QAI.0000000000002830","volume":"89","author":"J Piscitelli","year":"2022","unstructured":"Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, et al. Optimizing dolutegravir initiation in neonates using population pharmacokinetic modeling and simulation. J Acquir Immune Defic Syndr. 2022;89(1):108\u201314. https:\/\/doi.org\/10.1097\/QAI.0000000000002830.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"1653_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/QAI.0000000000003652","volume":"99","author":"TR Cressey","year":"2025","unstructured":"Cressey TR, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al. Single doses of pediatric dolutegravir dispersible tablets in neonates support multidosing: PETITE-dolutegravir study. J Acquir Immune Defic Syndr. 2025;99(2):195\u2013201. https:\/\/doi.org\/10.1097\/QAI.0000000000003652.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1653_CR40","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1016\/S2352-3018(25)00239-5","volume":"12","author":"A Bekker","year":"2025","unstructured":"Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al. Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1\/2 trial. Lancet HIV. 2025;12(11):e753\u201362. https:\/\/doi.org\/10.1016\/S2352-3018(25)00239-5.","journal-title":"Lancet HIV."},{"key":"1653_CR41","unstructured":"ClinicalTrials.gov. Open-label study of dolutegravir (DTG) or efavirenz (EFV) for human immunodeficiency virus (HIV) - tuberculosis (TB) co-infection, study ID: NCT02178592. Bethesda (MD): National Library of Medicine (US); 2014. https:\/\/clinicaltrials.gov\/study\/NCT02178592?id=NCT02178592&rank=1. Updated 1 Dec 2021; Cited 13 Feb 2025."},{"key":"1653_CR42","unstructured":"ClinicalTrials.gov. A trial comparing GSK1349572 50mg once daily to raltegravir 400mg twice daily (SPRING-2); study ID: NCT01227824. Bethesda (MD): National Library of Medicine (US); 2010. https:\/\/clinicaltrials.gov\/study\/NCT01227824?id=NCT01227824&rank=1. Updated 10 Sept 2018; Cited 13 Feb 2025."},{"issue":"9","key":"1653_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002895","volume":"16","author":"C Waitt","year":"2019","unstructured":"Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895. https:\/\/doi.org\/10.1371\/journal.pmed.1002895.","journal-title":"PLoS Med"},{"key":"1653_CR44","unstructured":"ClinicalTrials.gov. Phase IIa dose-ranging study of GSK1349572 in HIV-1 infected adults; study ID: NCT00708110. Bethesda (MD): National Library of Medicine (US); 2008. https:\/\/clinicaltrials.gov\/study\/NCT00708110. Updated 5 Dec 2013; Cited 13 Feb 2025."},{"key":"1653_CR45","unstructured":"ClinicalTrials.gov. A dose ranging trial of GSK1349572 and 2 NRTI in HIV-1 infected, therapy naive subjects (ING112276); study ID: NCT00951015. Bethesda (MD): National Library of Medicine (US); 2009. https:\/\/clinicaltrials.gov\/study\/NCT00951015?id=NCT00951015&rank=1. Updated 16 Jan 2018; Cited 13 Feb 2025."},{"key":"1653_CR46","unstructured":"ClinicalTrials.gov. ADVANCE study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in first-line antiretroviral therapy (ADVANCE), study ID: NCT03122262. Bethesda (MD): National Library of Medicine (US); 2017. https:\/\/clinicaltrials.gov\/study\/NCT03122262?id=NCT03122262&rank=1. Updated 8 Feb 2023; Cited 13 Feb 2025."},{"key":"1653_CR47","unstructured":"ClinicalTrials.gov. Switch study to evaluate dolutegravir plus lamivudine in virologically suppressed human immunodeficiency virus type 1 positive adults (TANGO), study ID: NCT03446573. Bethesda (MD): National Library of Medicine (US); 2018. https:\/\/clinicaltrials.gov\/study\/NCT03446573?id=NCT03446573&rank=1. Updated 19 July 2023; Cited 13 Dec 2025."},{"key":"1653_CR48","unstructured":"ClinicalTrials.gov. A pilot study assessing the integrase inhibitor GSK1349572 in HIV-infected persons with virus resistant to raltegravir, study ID: NCT00950859. Bethesda (MD): National Library of Medicine (US); 2009. https:\/\/clinicaltrials.gov\/study\/NCT00950859?id=NCT00950859&rank=1. Updated 12 Apr 2015; Cited 13 Feb 2025."},{"key":"1653_CR49","unstructured":"ClinicalTrials.gov. A study to assess dolutegravir in HIV-infected subjects with treatment failure on an integrase inhibitor containing regimen. (VIKING-3), study ID: NCT01328041. Bethesda (MD): National Library of Medicine (US); 2011. https:\/\/clinicaltrials.gov\/study\/NCT01328041?id=NCT01328041&rank=1. Updated 7 Jan 2016; Cited 13 Feb 2025."},{"key":"1653_CR50","unstructured":"ClinicalTrials.gov. A study of GSK1349572 versus raltegravir (RAL) with investigator selected background regimen in antiretroviral-experienced, integrase inhibitor-naive adults (SAILING), study ID: NCT01231516. Bethesda (MD): National Library of Medicine (US); 2010. https:\/\/clinicaltrials.gov\/study\/NCT01231516?id=NCT01231516&rank=1. Updated 15 Mar 2022; Cited 13 Feb 2025."},{"key":"1653_CR51","unstructured":"ClinicalTrials.gov. Study assessing dolutegravir in HIV-1 infected subjects with virus resistant to raltegravir and\/or elivitegravir (VIKING-4), study ID: NCT01568892. Bethesda (MD): National Library of Medicine (US); 2012. https:\/\/clinicaltrials.gov\/study\/NCT01568892?id=NCT01568892&rank=1. Updated 2 July 2018; Cited 13 Feb 2025."},{"key":"1653_CR52","unstructured":"ClinicalTrials.gov. Strategy for maintenance of HIV suppression with once daily integrate inhibitor+darunavir\/ritonavir in children (SMILE), study ID: NCT02383108. Bethesda (MD): National Library of Medicine (US); 2015. https:\/\/clinicaltrials.gov\/study\/NCT02383108?id=NCT02383108&rank=1. Updated 30 Mar 2021; Cited 13 Feb 2025."},{"key":"1653_CR53","unstructured":"ClinicalTrials.gov. Safety of and immune response to dolutegravir in HIV-1 infected infants, children, and adolescents, study ID: NCT01302847. Bethesda (MD): National Library of Medicine (US); 2011. https:\/\/clinicaltrials.gov\/study\/NCT01302847?id=NCT01302847&rank=1. Updated 12 Dec 2024; Cited 13 Feb 2025."},{"key":"1653_CR54","unstructured":"ClinicalTrials.gov. A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART, study ID: NCT02259127. Bethesda (MD): National Library of Medicine (US); 2014. https:\/\/clinicaltrials.gov\/study\/NCT02259127?id=NCT02259127&rank=1. Updated 29 Apr 2021; Cited 13 Feb 2025."},{"key":"1653_CR55","unstructured":"ClinicalTrials.gov. Pharmacokinetic study of antiretroviral drugs and related drugs during and after pregnancy, study ID: NCT00042289. Bethesda (MD): National Library of Medicine (US); 2002. https:\/\/clinicaltrials.gov\/study\/NCT00042289?id=NCT00042289&rank=1. Updated 22 July 2022. Cited 13 Feb 2025."},{"issue":"6","key":"1653_CR56","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cpdd.332","volume":"6","author":"AM Buchanan","year":"2017","unstructured":"Buchanan AM, Holton M, Conn I, Davies M, Choukour M, Wynne BR. Relative bioavailability of a dolutegravir dispersible tablet and the effects of low- and high-mineral-content water on the tablet in healthy adults. Clin Pharmacol Drug Dev. 2017;6(6):577\u201383. https:\/\/doi.org\/10.1002\/cpdd.332.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1653_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25\u201336. https:\/\/doi.org\/10.2133\/dmpk.24.25.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"11","key":"1653_CR58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-20","volume":"64","author":"MT Chirehwa","year":"2020","unstructured":"Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, et al. Population pharmacokinetics of cycloserine and pharmacokinetic\/pharmacodynamic target attainment in multidrug-resistant tuberculosis patients dosed with terizidone. Antimicrob Agents Chemother. 2020;64(11):e01381-20. https:\/\/doi.org\/10.1128\/AAC.01381-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1653_CR59","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(22)00044-3","volume":"9","author":"TD Ruel","year":"2022","unstructured":"Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montanez N, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. The Lancet HIV. 2022;9(5):e332\u201340. https:\/\/doi.org\/10.1016\/S2352-3018(22)00044-3.","journal-title":"The Lancet HIV"},{"issue":"9893","key":"1653_CR60","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(13)61221-0.","journal-title":"Lancet"},{"issue":"9868","key":"1653_CR61","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(12)61853-4.","journal-title":"Lancet"},{"issue":"2","key":"1653_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","volume":"12","author":"J van Lunzen","year":"2012","unstructured":"van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(11)70290-0.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"1653_CR63","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/bcp.14694","volume":"87","author":"RE Wasmann","year":"2021","unstructured":"Wasmann RE, Svensson EM, Walker AS, Clements MN, Denti P. Constructing a representative in-silico population for paediatric simulations: application to HIV-positive African children. Br J Clin Pharmacol. 2021;87(7):2847\u201354. https:\/\/doi.org\/10.1111\/bcp.14694.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1653_CR64","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","volume":"10","author":"R Griesel","year":"2023","unstructured":"Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023;10(7):e433\u201341. https:\/\/doi.org\/10.1016\/S2352-3018(23)00081-4.","journal-title":"Lancet HIV"},{"issue":"8","key":"1653_CR65","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1016\/S2352-3018(23)00107-8","volume":"10","author":"KM Brooks","year":"2023","unstructured":"Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1\u20132 dose-confirmation study. Lancet HIV. 2023;10(8):e506\u201317. https:\/\/doi.org\/10.1016\/S2352-3018(23)00107-8.","journal-title":"Lancet HIV."},{"issue":"5","key":"1653_CR66","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2352-3018(21)00292-7","volume":"9","author":"H Waalewijn","year":"2022","unstructured":"Waalewijn H, Chan MK, Bollen PDJ, Mujuru HA, Makumbi S, Kekitiinwa AR, et al. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022;9(5):e341\u201352. https:\/\/doi.org\/10.1016\/S2352-3018(21)00292-7.","journal-title":"Lancet HIV."},{"issue":"5","key":"1653_CR67","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cpt.2709","volume":"112","author":"KM Mantila","year":"2022","unstructured":"Mantila KM, Pasmooij AMG, Hallgreen CE, Mol PGM, van Boven JFM. Medication adherence measurement methods in registration trials supporting the approval of new medicines: a cross-sectional analysis of centralized procedures in the European Union 2010\u20132020. Clin Pharmacol Ther. 2022;112(5):1051\u201360. https:\/\/doi.org\/10.1002\/cpt.2709.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1653_CR68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/10543400500508705","volume":"16","author":"K Ogungbenro","year":"2006","unstructured":"Ogungbenro K, Aarons L, Graham G. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments. J Biopharm Stat. 2006;16(2):135\u201350. https:\/\/doi.org\/10.1080\/10543400500508705.","journal-title":"J Biopharm Stat"},{"issue":"3-4","key":"1653_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF03192320","volume":"25","author":"EO Fadiran","year":"2000","unstructured":"Fadiran EO, Jones CD, Ette EI. Designing population pharmacokinetic studies: performance of mixed designs. Eur J Drug Metab Pharmacokinet. 2000;25(3\u20134):231\u20139. https:\/\/doi.org\/10.1007\/BF03192320.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"1653_CR70","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1093\/jac\/dkv245","volume":"70","author":"E Dailly","year":"2015","unstructured":"Dailly E, Allavena C, Gregoire M, Reliquet V, Bouquie R, Billaud E, et al. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. J Antimicrob Chemother. 2015;70(12):3307\u201310. https:\/\/doi.org\/10.1093\/jac\/dkv245.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1653_CR71","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1128\/AAC.00073-11","volume":"55","author":"I Song","year":"2011","unstructured":"Song I, Borland J, Min S, Lou Y, Chen S, Patel P, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55(7):3517\u201321. https:\/\/doi.org\/10.1128\/AAC.00073-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1653_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3851\/IMP3119","volume":"22","author":"D Cattaneo","year":"2017","unstructured":"Cattaneo D, Minisci D, Cozzi V, Riva A, Meraviglia P, Clementi E, et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017;22(4):353\u20136. https:\/\/doi.org\/10.3851\/IMP3119.","journal-title":"Antivir Ther"},{"issue":"2","key":"1653_CR73","first-page":"56","volume":"18","author":"N Alanazi","year":"2024","unstructured":"Alanazi N, Hanif A. Prevalence of co-infection of human immunodeficiency virus in diagnosed tuberculosis cases: meta-analysis. Int J Health Sci (Qassim). 2024;18(2):56\u201361.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"5","key":"1653_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064915","volume":"8","author":"J Gao","year":"2013","unstructured":"Gao J, Zheng P, Fu H. Prevalence of TB\/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS ONE. 2013;8(5):e64915. https:\/\/doi.org\/10.1371\/journal.pone.0064915.","journal-title":"PLoS ONE"},{"key":"1653_CR75","unstructured":"Tibbetts E, Agus MSD. Pharmacokinetics in Children [Internet]. Merck Manuals; 2025. https:\/\/www.merckmanuals.com\/professional\/pediatrics\/principles-of-drug-treatment-in-children\/pharmacokinetics-in-children. Cited 3 Oct 2025."},{"issue":"6","key":"1653_CR76","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","volume":"32","author":"N Mulligan","year":"2018","unstructured":"Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729\u201337. https:\/\/doi.org\/10.1097\/QAD.0000000000001755.","journal-title":"AIDS"},{"issue":"2","key":"1653_CR77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","volume":"54","author":"X Wang","year":"2019","unstructured":"Wang X, Cerrone M, Ferretti F, Castrillo N, Maartens G, McClure M, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202\u20136. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.009.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1653_CR78","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1124\/dmd.110.037192","volume":"39","author":"SJ Miyagi","year":"2011","unstructured":"Miyagi SJ, Collier AC. The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos. 2011;39(5):912\u20139. https:\/\/doi.org\/10.1124\/dmd.110.037192.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1653_CR79","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/bj1960257","volume":"196","author":"N Kawade","year":"1981","unstructured":"Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J. 1981;196(1):257\u201360. https:\/\/doi.org\/10.1042\/bj1960257.","journal-title":"Biochem J"},{"issue":"1","key":"1653_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/00498250701744633","volume":"38","author":"H Jeong","year":"2008","unstructured":"Jeong H, Choi S, Song JW, Chen H, Fischer JH. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38(1):62\u201375. https:\/\/doi.org\/10.1080\/00498250701744633.","journal-title":"Xenobiotica"},{"issue":"01","key":"1653_CR81","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4236\/ojmm.2023.131011","volume":"13","author":"A Wanjiku","year":"2023","unstructured":"Wanjiku A, Mwamburi L, Ngeiywa M, Obala A. Variation in progesterone levels and urinary tract infections in pregnant women attending Moi Teaching and referral Hospital, Eldoret, Kenya. Open J Med Microbiol. 2023;13(01):125\u201335. https:\/\/doi.org\/10.4236\/ojmm.2023.131011.","journal-title":"Open J Med Microbiol."},{"issue":"1","key":"1653_CR82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.1109","volume":"105","author":"DK Bhatt","year":"2019","unstructured":"Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, et al. Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-hlucuronosyltransferases in human liver. Clin Pharmacol Ther. 2019;105(1):131\u201341. https:\/\/doi.org\/10.1002\/cpt.1109.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1653_CR83","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","volume":"39","author":"M Feghali","year":"2015","unstructured":"Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512\u20139. https:\/\/doi.org\/10.1053\/j.semperi.2015.08.003.","journal-title":"Semin Perinatol"},{"issue":"2","key":"1653_CR84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW van Valkengoed","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ. All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology. Clin Pharmacokinet. 2025;64(2):173\u201392. https:\/\/doi.org\/10.1007\/s40262-024-01444-6.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1653_CR85","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/bcp.13230","volume":"83","author":"NH Holford","year":"2017","unstructured":"Holford NH, Anderson BJ. Why standards are useful for predicting doses. Br J Clin Pharmacol. 2017;83(4):685\u20137. https:\/\/doi.org\/10.1111\/bcp.13230.","journal-title":"Br J Clin Pharmacol"},{"key":"1653_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2020.11.006","volume":"37","author":"Y Enoki","year":"2021","unstructured":"Enoki Y, Kishi N, Sakamoto K, Uchiyama E, Hayashi Y, Suzuki N, et al. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions. Drug Metab Pharmacokinet. 2021;37:100371. https:\/\/doi.org\/10.1016\/j.dmpk.2020.11.006.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1653_CR87","unstructured":"Mirochnick M. (Protocol Chair). Pharmacokinetic properties of antiretroviral and related drugs during pregnancy and postpartum (NCT00042289). Clinical trial protocol. Bethesda, MD: ClinicalTrials.gov; 2016. https:\/\/cdn.clinicaltrials.gov\/large-docs\/89\/NCT00042289\/Prot_001.pdf."},{"key":"1653_CR88","unstructured":"Khoo S. (Chief Investigator\/Protocol Chair). Safety and pharmacokinetics of dolutegravir in pregnant HIV mothers and their neonates: a pilot study (NCT02245022). Clinical trial protocol. Bethesda, MD: ClinicalTrials.gov; 2017. https:\/\/cdn.clinicaltrials.gov\/large-docs\/22\/NCT02245022\/Prot_SAP_000.pdf."},{"key":"1653_CR89","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212608","volume":"8","author":"A Ruggiero","year":"2019","unstructured":"Ruggiero A, Ariano A, Triarico S, Capozza MA, Ferrara P, Attina G. Neonatal pharmacology and clinical implications. Drugs Context. 2019;8:212608. https:\/\/doi.org\/10.7573\/dic.212608.","journal-title":"Drugs Context."},{"key":"1653_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"1653_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11060259","volume":"11","author":"HM Back","year":"2019","unstructured":"Back HM, Lee JB, Han N, Goo S, Jung E, Kim J, et al. Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients. Pharmaceutics. 2019;11(6):259. https:\/\/doi.org\/10.3390\/pharmaceutics11060259.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1653_CR92","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.12741","volume":"80","author":"K O'Hara","year":"2015","unstructured":"O\u2019Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol. 2015;80(6):1281\u20138. https:\/\/doi.org\/10.1111\/bcp.12741.","journal-title":"Br J Clin Pharmacol"},{"key":"1653_CR93","unstructured":"World Health Organization (WHO). Tuberculosis & HIV\u2014Global HIV Programme [Internet]. World Health Organization (WHO). https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/tuberculosis-hiv. Cited 9 Oct 2025."},{"issue":"9","key":"1653_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01043-21","volume":"65","author":"V Tuloup","year":"2021","unstructured":"Tuloup V, France M, Garreau R, Bleyzac N, Bourguignon L, Tod M, et al. Model-based comparative analysis of rifampicin and rifabutin drug-drug interaction profile. Antimicrob Agents Chemother. 2021;65(9):e0104321. https:\/\/doi.org\/10.1128\/AAC.01043-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1653_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113998","volume":"21","author":"M Cipriano","year":"2020","unstructured":"Cipriano M, Pinheiro PF, Sequeira CO, Rodrigues JS, Oliveira NG, Antunes AMM, et al. Nevirapine biotransformation insights: an integrated in vitro approach unveils the biocompetence and glutathiolomic profile of a human hepatocyte-like cell 3D model. Int J Mol Sci. 2020;21(11):3998. https:\/\/doi.org\/10.3390\/ijms21113998.","journal-title":"Int J Mol Sci"},{"key":"1653_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114636","volume":"162","author":"NHC Loos","year":"2023","unstructured":"Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023;162:114636. https:\/\/doi.org\/10.1016\/j.biopha.2023.114636.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1653_CR97","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","volume":"42","author":"MM Foisy","year":"2008","unstructured":"Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42(7):1048\u201359. https:\/\/doi.org\/10.1345\/aph.1K615.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"1653_CR98","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dkw032","volume":"71","author":"C Marzolini","year":"2016","unstructured":"Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755\u20138. https:\/\/doi.org\/10.1093\/jac\/dkw032.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1653_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.106.112136","volume":"320","author":"SR Faucette","year":"2007","unstructured":"Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320(1):72\u201380. https:\/\/doi.org\/10.1124\/jpet.106.112136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"1653_CR100","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","volume":"62","author":"AH Tolson","year":"2010","unstructured":"Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62(13):1238\u201349. https:\/\/doi.org\/10.1016\/j.addr.2010.08.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"1653_CR101","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000004223","volume":"39","author":"S Abdalla","year":"2025","unstructured":"Abdalla S, Compagnucci A, Bamford A, Chan MK, Ramos JT, Riault Y, et al. Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents. AIDS. 2025;39(10):1385\u201391. https:\/\/doi.org\/10.1097\/QAD.0000000000004223.","journal-title":"AIDS"},{"key":"1653_CR102","unstructured":"Alladio F, Ferrara M, Accardo G, Fantino S, Trevisan G, Drappero E, et al. Dolutegravir plasma and intracellular pharmacokinetics in the clinical setting (abstract 29). 23th international workshop on clinical pharmacology of HIV, hepatitis and other antiviral drugs. Barcelona, Spain; 2022."},{"issue":"2","key":"1653_CR103","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0022-3565(25)12089-2","volume":"275","author":"EG Schuetz","year":"1995","unstructured":"Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275(2):1011\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1653_CR104","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0895-4356(92)90081-w","volume":"45","author":"ME Salive","year":"1992","unstructured":"Salive ME, Cornoni-Huntley J, Phillips CL, Guralnik JM, Cohen HJ, Ostfeld AM, et al. Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol. 1992;45(3):213\u201321. https:\/\/doi.org\/10.1016\/0895-4356(92)90081-w.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1653_CR105","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1600-0773.1998.tb01401.x","volume":"82","author":"PH Villard","year":"1998","unstructured":"Villard PH, Herber R, Seree EM, Attolini L, Magdalou J, Lacarelle B. Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol. 1998;82(2):74\u20139. https:\/\/doi.org\/10.1111\/j.1600-0773.1998.tb01401.x.","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"1653_CR106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0168-8278(02)00359-8","volume":"38","author":"PJ Bosma","year":"2003","unstructured":"Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003;38(1):107\u201317. https:\/\/doi.org\/10.1016\/s0168-8278(02)00359-8.","journal-title":"J Hepatol"},{"issue":"1","key":"1653_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/pgs.13.190","volume":"15","author":"S Chen","year":"2014","unstructured":"Chen S, St Jean P, Borland J, Song I, Yeo AJ, Piscitelli S, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15(1):9\u201316. https:\/\/doi.org\/10.2217\/pgs.13.190.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1653_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2717-x","volume":"17","author":"H Yagura","year":"2017","unstructured":"Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. https:\/\/doi.org\/10.1186\/s12879-017-2717-x.","journal-title":"BMC Infect Dis"},{"issue":"4_suppl","key":"1653_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.294","volume":"43","author":"C Mo","year":"2025","unstructured":"Mo C, Kuang C, Moon J, Zhang C, Raj S, Bteich F, et al. UGT1A1 mutation rates in a minority-rich comprehensive cancer center: a retrospective pharmacogenomic study. J Clin Oncol. 2025;43(4_suppl):294. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.294.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1653_CR110","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1479-7364-4-4-238","volume":"4","author":"SC Marques","year":"2010","unstructured":"Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics. 2010;4(4):238\u201349. https:\/\/doi.org\/10.1186\/1479-7364-4-4-238.","journal-title":"Hum Genomics"},{"key":"1653_CR111","unstructured":"World Health Organization (WHO). Dolutegravir (DTG) Paediatric Dosing Information: Paediatric ARV Drug Optimization (PADO); 2021. https:\/\/paedsarvdosing.org\/wp-content\/uploads\/2021\/12\/DTG.pdf"},{"key":"1653_CR112","unstructured":"Momper J, Chandasana H, Wang J, Johnston B, Bradford S, Yin DE, et al. PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023). Conference on Retroviruses and Opportunistic Infections (CROI). San Francisco, California; 2025. https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/posters\/2025\/1047-2025.pdf."},{"issue":"8","key":"1653_CR113","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/QAD.0000000000001459","volume":"31","author":"A Menard","year":"2017","unstructured":"Menard A, Montagnac C, Solas C, Meddeb L, Dhiver C, Tomei C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS. 2017;31(8):1201\u20133. https:\/\/doi.org\/10.1097\/QAD.0000000000001459.","journal-title":"AIDS"},{"key":"1653_CR114","first-page":"61","volume":"5","author":"C Solas","year":"2017","unstructured":"Solas C, Bregigeon S, Faucher-Zaegel O, Laroche H, Obry-Roguet V, Quaranta S, et al. Higher dolutegravir plasma trough concentration (Ctrough) in patients presenting side effects: interest of therapeutic drug monitoring? (Abstract P_59). Rev Antivir Ther Infect Dis. 2017;5:61.","journal-title":"Rev Antivir Ther Infect Dis."},{"key":"1653_CR115","unstructured":"Yagura H, Watanabe D, Nakauchi T, Tomishima K, Kasai D, Nishida Y, et al. Effect of dolutegravir plasma concentrations on central nervous system side effects (Poster 426). Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington; 2017. https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/posters\/2017\/426_Yagura.pdf."},{"issue":"1","key":"1653_CR116","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21\u20137. https:\/\/doi.org\/10.1097\/QAI.0b013e318276cda9.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1653_CR117","unstructured":"ClinicalTrials.gov. A study of the safety, tolerability, and pharmacokinetics of dolutegravir in neonates exposed to HIV-1; study ID: NCT05406583. Bethesda (MD): National Library of Medicine (US); 2022. https:\/\/clinicaltrials.gov\/study\/NCT05406583?term=IMPAACT%202023&rank=1&a=1. Updated 29 Aug 2025. Cited 9 Dec 2025."},{"issue":"5","key":"1653_CR118","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/QAI.0000000000002492","volume":"85","author":"DF Clarke","year":"2020","unstructured":"Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, et al. Impact of low birth weight and prematurity on neonatal Raltegravir pharmacokinetics: Impaact P1097. J Acquir Immune Defic Syndr. 2020;85(5):626\u201334. https:\/\/doi.org\/10.1097\/QAI.0000000000002492.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"1653_CR119","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3851\/IMP3139","volume":"22","author":"D Kreutzwiser","year":"2017","unstructured":"Kreutzwiser D, Sheehan N, Dayneka N, Lemire B, Wong A, Samson L, et al. Therapeutic drug monitoring guided Raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV. Antivir Ther. 2017;22(6):545\u20139. https:\/\/doi.org\/10.3851\/IMP3139.","journal-title":"Antivir Ther"},{"issue":"11","key":"1653_CR120","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/QAD.0000000000003973","volume":"38","author":"EM King","year":"2024","unstructured":"King EM, Tkachuk S, Tseng A. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV. AIDS. 2024;38(11):1609\u201316. https:\/\/doi.org\/10.1097\/QAD.0000000000003973.","journal-title":"AIDS"},{"issue":"10","key":"1653_CR121","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/17425255.2022.2132931","volume":"18","author":"T Zhang","year":"2022","unstructured":"Zhang T, Krekels EHJ, Smit C, Knibbe CAJ. Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes. Expert Opin Drug Metab Toxicol. 2022;18(10):657\u201374. https:\/\/doi.org\/10.1080\/17425255.2022.2132931.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1653_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad361","volume":"10","author":"M Berton","year":"2023","unstructured":"Berton M, Bettonte S, Stader F, Battegay M, Marzolini C. Impact of obesity on the drug-drug interaction between dolutegravir and rifampicin or any other strong inducers. Open Forum Infect Dis. 2023;10(7):ofad361. https:\/\/doi.org\/10.1093\/ofid\/ofad361.","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01653-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:57Z","timestamp":1783748217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01653-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01653-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00c9milie Pilote received scholarships from the Faculty of Pharmacy of Universit\u00e9 de Montr\u00e9al.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"\u00c9milie Pilote declares no conflicts of interest. Nancy L. Sheehan has received travel grants, speaker honorarium, and consultant fees from ViiV Healthcare Canada. Am\u00e9lie Marsot is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"\u00c9.P. performed the literature search, analyzed the data, and wrote the manuscript. N.L.S. and A.M. validated the manuscript and supervised the work. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}